A Phase 3 interventional study of ABL001 40mg BID and ABL001 80mg QD in Chronic Myelogenous Leukemia, sponsored by Novartis Pharmaceuticals. Completed at 48 sites in 16 countries. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-03-18.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing asciminib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive — 8 open to participants now, 13 under way, 2 of them phase 3. asciminib · Leukemia, Myelogenous, Chronic, BCR-ABL Positive.
Among the 21 studies testing asciminib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive, this one is the 6th largest by enrollment, is one of 5 that started in 2021, is one of 5 in phase 3, and was the 12th registered.
894 studies on the registry are indexed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive; 109 are open to participants now.
Browse Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies →8 of the 21 studies testing asciminib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive are open now, in 12 countries. Recruiting first, the newest first:
Thomas Ernst, Prof. Dr. med. · Sites in Germany
Ages 18+
Novartis Pharmaceuticals · Sites in United States, Australia, Brazil and 14 more countries
Ages 1–18
Gruppo Italiano Malattie EMatologiche dell'Adulto · Sites in Spain
Ages 18+
Novartis Pharmaceuticals · Sites in France
Ages 18–99
M.D. Anderson Cancer Center · Sites in United States
Ages 18+
By country, each count listing its studies:
asciminib: first FDA approval 2021 (SCEMBLIX), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →
Of the 79 Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies recruiting now, 48 (61%) set no upper age limit and 20 (25%) stop at 75 or younger; 20 take children under 18; 7 take healthy volunteers.
This study: 18 Years to 99 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 12 · Phase 3 5 · Phase 4 2
First in 2014; this study’s year is marked. 5 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 199 is above the median of 44 across 681 interventional studies indexed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive.
Median enrollment 100 across the 21 interventional studies. Of the 8 that completed or were terminated, 4 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 21 have an industry lead sponsor. The 9 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
92 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive by Novartis: 9 open now, 13 under way, 2 of them phase 3. Of 73 finished, 35 (48%) have results posted.
Among the 92 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive by Novartis, this one is the 19th largest by enrollment of the 63 interventional ones that give a count, is one of 8 that started in 2021, is one of 19 in phase 3, and was the 69th registered.
Novartis’s Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies by the year they started, since 1999.
2 of the studies testing asciminib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03906292University of JenaFrontline Asciminib Combination in Chronic Phase CML | 2027-03 |
| NCT04925479Novartis PharmaceuticalsStudy to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia | 2027-09-03 |
Add all 2 to your calendar (.ics) → With an account.
Among the 21 studies testing asciminib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive, from their registry updates:
Among Novartis’s 92 in Leukemia, Myelogenous, Chronic, BCR-ABL Positive:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to optimize the treatment of asciminib in patients with chronic myelogenous leukemia in chronic phase (CML-CP) previously treated with 2 or more Tyrosine Kinase Inhibitors (TKIs).
This study consists of a screening period of up to 28 days, a treatment period of 144 weeks and a post-treatment safety follow-up period of 4 weeks.
Patients will receive asciminib as study treatment continuously for up to 144 weeks or until disease progression, treatment failure or intolerance to treatment. At treatment initiation, asciminib will be provided to all trial patients at a total daily dose of 80 mg. All patients will be randomly assigned 1:1 to 2 groups with 80 mg given either as 40 mg b.i.d. or 80 mg q.d., using IRT to avoid any selection bias.
In patients not achieving Major Molecular Responses (MMR) at 48 weeks or losing the response after the week 48 assessment up to week 108, asciminib dose may be escalated to 200 mg q.d. if in the investigator's opinion the patient may benefit from the escalation. In addition, there must not be any grade 3 or 4 toxicity while on therapy, or persistent grade 2 toxicity, possibly related to asciminib and unresponsive to optimal management.
The trial will enroll a total of approximately 186 patients:
Key Inclusion criteria:
Key Exclusion criteria:
Other Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will be treated with 80 mg of ABL001 (40 mg BID or 80mg QD). In patients not achieving MMR at 48 weeks or losing the response after the week 48 assessment up to week 108, asciminib dose may be escalated to 200 mg q.d. if in the investigator's opinion the patient may benefit from the escalation.
Drug: ABL001 40mg BID · Drug: ABL001 80mg QD · Drug: ABL001 200mg QD
One tablet of 40 mg will be taken orally twice a day (BID)
Also known as: asciminib
Two tablets of 40 mg will be taken orally once a day (QD)
Also known as: asciminib
Five tablets of 40 mg will be taken orally once a day (QD)
Also known as: asciminib
Major Molecular Response (MMR) Rate at Week 48 for All Patients With no Evidence of MMR at Baseline
Major Molecular Response (MMR) is defined as a significant reduction in the level of BCR::ABL1 transcripts, which are the genetic markers of chronic myeloid leukemia (CML). Specifically, MMR is achieved when there is a ≥ 3.0 log reduction in BCR::ABL1 transcripts compared to a standardized baseline, which corresponds to a BCR::ABL1/ABL1 ratio of ≤ 0.1% on the international scale (IS). The Major Molecular Response (MMR) rate at Week 48 for all patients with no evidence of MMR at baseline refers to the percentage of patients who achieve MMR after 48 weeks of treatment, despite not having MMR at the start.
Time frame: Week 48
MMR Rate at Week 12, 24, 36, 72, 96 and 144 for Patients With no MMR at Baseline
The Major Molecular Response (MMR) rate at alternative time points (weeks 12, 24, 36, 72, 96 and 144) for all patients with no evidence of MMR at baseline refers to the percentage of patients who achieve MMR after those respective weeks of treatment, despite not having MMR at the start. MMR itself is defined as achieving a BCR::ABL1 ratio of ≤ 0.1%.
Time frame: Week 12, 24, 36, 72, 96 and 144
Major Molecular Response (MMR) Rate at Week 48 for Patients With MMR at Baseline
The Major Molecular Response (MMR) rate at Week 48 for patients with MMR at baseline refers to the percentage of patients who maintain or achieve MMR after 48 weeks of treatment. MMR itself is defined as achieving a BCR::ABL1 ratio of ≤ 0.1%.
Time frame: Week 48.
Time to MMR for Subjects Without MMR at Baseline
Time to MMR defined as the time from the date of randomization to the date of the first documented MMR. MMR itself is defined as achieving a BCR::ABL1 ratio of ≤ 0.1%.
Time frame: From the date of enrollment to the date of first documented MMR, assessed up to 144 weeks
Rate of BCR::ABL1 ≤ 10% for Subjects Without MMR at Baseline
The rate of BCR::ABL1 ≤ 10% refers to the percentage of patients who achieve a BCR::ABL1 level of 10% or lower within the first 48 weeks of treatment.
Time frame: Week 12, 24, 36 and 48
Rate of BCR::ABL1 ≤ 1% for Subjects Without MMR at Baseline
The rate of BCR::ABL1 ≤ 1% refers to the percentage of patients who achieve a BCR::ABL1 level of 1% or lower within the first 48 weeks of treatment.
Time frame: Week 12, 24, 36 and 48.
Deep Molecular Responses (MR4) Rate for Subjects Without MMR at Baseline
Deep molecular responses (MR4) is defined as a ≥ 4 log reduction in BCR::ABL1 transcripts compared to the standardized baseline, equivalent to 0.01% BCR::ABL1/ABL1 by the international scale (IS).
Time frame: Week 12, 24, 36, 48, 72, 96 and 144.
Deep Molecular Responses (MR4.5) Rate for Subjects Without MMR at Baseline
Deep molecular responses (MR4.5) is defined as a ≥ 4.5 log reduction in BCR::ABL1 transcripts compared to the standardized baseline, equivalent to 0.0032% BCR::ABL1/ABL1 by the international scale (IS).
Time frame: Week 12, 24, 36, 48, 72, 96 and 144.
Rate of Complete Cytogenetic Response (CCyR) for Subjects Without MMR at Baseline
Cytogenetic Response is assessed based on the percentage of Philadelphia chromosome-positive (Ph+) metaphases in the bone marrow, with a review of at least 20 metaphases required. Complete Cytogenetic Response (CCyR) is defined as 0% Ph+ metaphases in the bone marrow.
Time frame: Week 48 and end of treatment (up to 144 weeks)
Occurrence of High-risk Additional Chromosomal Abnormalities (ACA) for Subjects Without MMR at Baseline
High-risk additional chromosomal abnormalities (ACAs) are specific chromosomal abnormalities that are considered to increase the risk in Philadelphia chromosome-positive (Ph+) cells.
Time frame: Up to 144 weeks
Cumulative Molecular Response Rate of BCR::ABL1 ≤ 10% for Subjects Without MMR at Baseline
The cumulative molecular response rate refers to the proportion of subjects achieving a BCR::ABL1 level of ≤ 10% on the international scale (IS) over a specified period.
Time frame: From enrollment to end of treatment up to 144 weeks.
Cumulative Molecular Response Rate of BCR::ABL1 ≤1% for Subjects Without MMR at Baseline
The cumulative molecular response rate refers to the proportion of subjects achieving a BCR::ABL1 level of ≤ 1% on the international scale (IS) over a specified period.
Time frame: From enrollment to end of treatment up to 144 weeks.
Cumulative Molecular Response Rate of MMR for Subjects Without MMR at Baseline
The cumulative molecular response rate refers to the proportion of subjects achieving MMR, defined as a BCR::ABL1 ratio of ≤ 0.1% on the international scale (IS), over a specified period.
Time frame: From enrollment to end of treatment up to 144 weeks.
Cumulative Molecular Response Rate of MR4 for Subjects Without MMR at Baseline
The cumulative molecular response rate refers to the proportion of subjects achieving MR4, defined as a ≥ 4 log reduction in BCR::ABL1 transcripts compared to the standardized baseline, equivalent to 0.01% BCR::ABL1/ABL1 by the international scale (IS), over a specified period.
Time frame: From enrollment to end of treatment up to 144 weeks.
Cumulative Molecular Response Rate of MR4.5 for Subjects Without MMR at Baseline
The cumulative molecular response rate refers to the proportion of subjects achieving MR4.5, defined as a ≥ 4.5 log reduction in BCR::ABL1 transcripts compared to the standardized baseline, equivalent to 0.0032% BCR::ABL1/ABL1 by the international scale (IS), over a specified period.
Time frame: From enrollment to end of treatment up to 144 weeks.
Duration of MMR
Duration of MMR is defined as the time from the date of first documented MMR to the earliest date of loss of MMR, progression to accelerated phase (AP) or blast crisis (BC), or CML-related death. The duration of MMR is analyzed for the subjects in FAS who achieved MMR at any time.
Time frame: From the date of the first documented molecular response at MMR level to the date of first documented loss of the response level or death due to any cause, whichever occurs first, assessed up to 144 weeks.
Duration of MR4 Without Loss of MMR
Duration of MR4 without loss of MMR refers to the period during which a patient maintains a deep molecular response (MR4) without experiencing a loss of Major Molecular Response (MMR).
Time frame: From the date of first documented MR4 without loss of MMR to the date of first documented loss of the response level or death due to any cause, whichever occurs first, assessed up to 144 weeks.
Progression-Free Survival (PFS) for Subjects Without MMR at Baseline
Progression-Free Survival (PFS) is defined as the time from the date of randomization to the earliest occurrence of documented disease progression to AP/BC or the date of death from any cause, assessed up to approximately 144 weeks. The time will be censored at the date of last study assessment (PCR, cytogenetic, hematologic or extramedullary) or last post-treatment follow-up for subjects without event. PFS (in months) is calculated as: (date of disease progression/death or censoring date - date of randomization +1)/30.4375.
Time frame: Up to 144 weeks.
Overall Survival (OS) for Subjects Without MMR at Baseline
Overall Survival (OS) is defined as the time from treatment assignment to death due to any cause during study, assessed up to 144 weeks. Subjects who are alive at the time of the analysis data cutoff date will be censored at the date of last contact before the cut-off date. OS (in months) is calculated as: (date of death or censoring date - date of randomization + 1)/30.4375.
Time frame: Up to 144 weeks.
Time to Treatment Failure (TTF) for Subjects Without MMR at Baseline
Time from treatment assignment to treatment failure is defined as BCR-ABL1\>10%, assessed up to 144 weeks. For subjects who have not reached treatment failure, their TTFs will be censored at the time of last study assessment (PCR, cytogenetic, hematologic or extramedullary) before the cut-off date. TTF (in months) is calculated as: (date of treatment failure or censoring date - date of randomization + 1)/30.4375.
Time frame: Up to 144 weeks.
Change in Symptom Burden and Interference From Baseline Over Time According to the MDASI-CML PRO Instrument
The MD Anderson Symptom Inventory - Chronic Myeloid Leukemia (MDASI-CML) is a 26 item self-administered questionnaire for adult CML patients. Twenty of the items measure the severity of disease-related symptoms (symptom burden) and are scored from 0 (not present) to 10 (as bad as you can imagine) and 6 items that measure symptom interference with daily life (interference) scored from 0 (did not interfere) to 10 (interfered completely). For symptom burden, total scores range from 0 to 200 and for interference range from 0 to 60, with higher scores indicates high impact on severity of chronic myeloid leukemia-related symptoms and on impact of these symptoms on daily functioning for the patient.
Time frame: Week 4, 12, 24, 48, 72, 96, 120 and at end of treatment (up to 144 weeks).
The study is conducted globally across 16 countries.
| Milestone | Asciminib 40 mg b.i.d. - Subjects Without MMR at Baseline | Asciminib 80 mg q.d. - Subjects Without MMR at Baseline | Asciminib 40 mg b.i.d. - Subjects With MMR at Baseline | Asciminib 80 mg q.d. - Subjects With MMR at Baseline |
|---|---|---|---|---|
| Started | 85 | 84 | 14 | 16 |
| Full analysis set (fas) | 85 | 84 | 0 | 0 |
| Full analysis set 2 (fas 2) | 0 | 0 | 14 | 16 |
| Safety set (saf) | 84 | 84 | 0 | 0 |
| Safety set 2 (saf 2) | 0 | 0 | 14 | 16 |
| Completed | 0 | 0 | 0 | 0 |
| Not completed | 85 | 84 | 14 | 16 |
| Withdrew: Adverse event | 6 | 4 | 0 | 2 |
| Withdrew: Unsatisfactory therapeutic effect | 4 | 3 | 0 | 0 |
| Withdrew: Progressive disease | 1 | 5 | 0 | 0 |
| Withdrew: Physician decision | 2 | 2 | 0 | 0 |
| Withdrew: Failure to meet continuation criteria | 2 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 2 | 0 | 0 | 1 |
| Withdrew: Protocol violation | 0 | 1 | 0 | 0 |
| Withdrew: Treatment ongoing at the time of the data cut-off date 12-mar-2024 | 68 | 68 | 14 | 13 |
Major Molecular Response (MMR) is defined as a significant reduction in the level of BCR::ABL1 transcripts, which are the genetic markers of chronic myeloid leukemia (CML). Specifically, MMR is achieved when there is a ≥ 3.0 log reduction in BCR::ABL1 transcripts compared to a standardized baseline, which corresponds to a BCR::ABL1/ABL1 ratio of ≤ 0.1% on the international scale (IS). The Major Molecular Response (MMR) rate at Week 48 for all patients with no evidence of MMR at baseline refers to the percentage of patients who achieve MMR after 48 weeks of treatment, despite not having MMR at the start.
| Percentage of responders | Asciminib 40 mg b.i.d. - Subjects Without MMR at Baseline | Asciminib 80 mg q.d. - Subjects Without MMR at Baseline |
|---|---|---|
| Major Molecular Response (MMR) Rate at Week 48 for All Patients With no Evidence of MMR at Baseline | 42.35 (31.70 to 53.55) | 34.52 (24.48 to 45.69) |
The Major Molecular Response (MMR) rate at alternative time points (weeks 12, 24, 36, 72, 96 and 144) for all patients with no evidence of MMR at baseline refers to the percentage of patients who achieve MMR after those respective weeks of treatment, despite not having MMR at the start. MMR itself is defined as achieving a BCR::ABL1 ratio of ≤ 0.1%.
Results for this outcome have not been posted.
The Major Molecular Response (MMR) rate at Week 48 for patients with MMR at baseline refers to the percentage of patients who maintain or achieve MMR after 48 weeks of treatment. MMR itself is defined as achieving a BCR::ABL1 ratio of ≤ 0.1%.
| Percentage of responders | Asciminib 40 mg b.i.d. - Subjects Without MMR at Baseline | Asciminib 80 mg q.d. - Subjects Without MMR at Baseline |
|---|---|---|
| Major Molecular Response (MMR) Rate at Week 48 for Patients With MMR at Baseline | 100 (76.84 to 100.00) | 87.5 (61.65 to 98.45) |
Time to MMR defined as the time from the date of randomization to the date of the first documented MMR. MMR itself is defined as achieving a BCR::ABL1 ratio of ≤ 0.1%.
Results for this outcome have not been posted.
The rate of BCR::ABL1 ≤ 10% refers to the percentage of patients who achieve a BCR::ABL1 level of 10% or lower within the first 48 weeks of treatment.
| Percentage of BCR::ABL1 <= 10% | Asciminib 40 mg b.i.d. - Subjects Without MMR at Baseline | Asciminib 80 mg q.d. - Subjects Without MMR at Baseline |
|---|---|---|
| Week 12 | 69.4 (58.47 to 78.95) | 81.0 (70.92 to 88.70) |
| Week 24 | 72.9 (62.21 to 82.01) | 76.2 (65.65 to 84.81) |
| Week 36 | 71.8 (60.96 to 81.00) | 82.1 (72.26 to 89.65) |
| Week 48 | 71.8 (60.96 to 81.00) | 78.6 (68.26 to 86.78) |
The rate of BCR::ABL1 ≤ 1% refers to the percentage of patients who achieve a BCR::ABL1 level of 1% or lower within the first 48 weeks of treatment.
| Percentage of BCR::ABL1 ≤ 1% | Asciminib 40 mg b.i.d. - Subjects Without MMR at Baseline | Asciminib 80 mg q.d. - Subjects Without MMR at Baseline |
|---|---|---|
| Week 12 | 61.2 (49.99 to 71.56) | 53.6 (42.35 to 64.53) |
| Week 24 | 64.7 (53.59 to 74.77) | 58.3 (47.06 to 69.00) |
| Week 36 | 63.5 (52.38 to 73.71) | 64.3 (53.08 to 74.45) |
| Week 48 | 64.7 (53.59 to 74.77) | 59.5 (48.25 to 70.10) |
Deep molecular responses (MR4) is defined as a ≥ 4 log reduction in BCR::ABL1 transcripts compared to the standardized baseline, equivalent to 0.01% BCR::ABL1/ABL1 by the international scale (IS).
Results for this outcome have not been posted.
Deep molecular responses (MR4.5) is defined as a ≥ 4.5 log reduction in BCR::ABL1 transcripts compared to the standardized baseline, equivalent to 0.0032% BCR::ABL1/ABL1 by the international scale (IS).
Results for this outcome have not been posted.
Cytogenetic Response is assessed based on the percentage of Philadelphia chromosome-positive (Ph+) metaphases in the bone marrow, with a review of at least 20 metaphases required. Complete Cytogenetic Response (CCyR) is defined as 0% Ph+ metaphases in the bone marrow.
Results for this outcome have not been posted.
High-risk additional chromosomal abnormalities (ACAs) are specific chromosomal abnormalities that are considered to increase the risk in Philadelphia chromosome-positive (Ph+) cells.
Results for this outcome have not been posted.
The cumulative molecular response rate refers to the proportion of subjects achieving a BCR::ABL1 level of ≤ 10% on the international scale (IS) over a specified period.
Results for this outcome have not been posted.
The cumulative molecular response rate refers to the proportion of subjects achieving a BCR::ABL1 level of ≤ 1% on the international scale (IS) over a specified period.
Results for this outcome have not been posted.
The cumulative molecular response rate refers to the proportion of subjects achieving MMR, defined as a BCR::ABL1 ratio of ≤ 0.1% on the international scale (IS), over a specified period.
Results for this outcome have not been posted.
The cumulative molecular response rate refers to the proportion of subjects achieving MR4, defined as a ≥ 4 log reduction in BCR::ABL1 transcripts compared to the standardized baseline, equivalent to 0.01% BCR::ABL1/ABL1 by the international scale (IS), over a specified period.
Results for this outcome have not been posted.
The cumulative molecular response rate refers to the proportion of subjects achieving MR4.5, defined as a ≥ 4.5 log reduction in BCR::ABL1 transcripts compared to the standardized baseline, equivalent to 0.0032% BCR::ABL1/ABL1 by the international scale (IS), over a specified period.
Results for this outcome have not been posted.
Duration of MMR is defined as the time from the date of first documented MMR to the earliest date of loss of MMR, progression to accelerated phase (AP) or blast crisis (BC), or CML-related death. The duration of MMR is analyzed for the subjects in FAS who achieved MMR at any time.
Results for this outcome have not been posted.
Duration of MR4 without loss of MMR refers to the period during which a patient maintains a deep molecular response (MR4) without experiencing a loss of Major Molecular Response (MMR).
Results for this outcome have not been posted.
Progression-Free Survival (PFS) is defined as the time from the date of randomization to the earliest occurrence of documented disease progression to AP/BC or the date of death from any cause, assessed up to approximately 144 weeks. The time will be censored at the date of last study assessment (PCR, cytogenetic, hematologic or extramedullary) or last post-treatment follow-up for subjects without event. PFS (in months) is calculated as: (date of disease progression/death or censoring date - date of randomization +1)/30.4375.
Results for this outcome have not been posted.
Overall Survival (OS) is defined as the time from treatment assignment to death due to any cause during study, assessed up to 144 weeks. Subjects who are alive at the time of the analysis data cutoff date will be censored at the date of last contact before the cut-off date. OS (in months) is calculated as: (date of death or censoring date - date of randomization + 1)/30.4375.
Results for this outcome have not been posted.
Time from treatment assignment to treatment failure is defined as BCR-ABL1\>10%, assessed up to 144 weeks. For subjects who have not reached treatment failure, their TTFs will be censored at the time of last study assessment (PCR, cytogenetic, hematologic or extramedullary) before the cut-off date. TTF (in months) is calculated as: (date of treatment failure or censoring date - date of randomization + 1)/30.4375.
Results for this outcome have not been posted.
The MD Anderson Symptom Inventory - Chronic Myeloid Leukemia (MDASI-CML) is a 26 item self-administered questionnaire for adult CML patients. Twenty of the items measure the severity of disease-related symptoms (symptom burden) and are scored from 0 (not present) to 10 (as bad as you can imagine) and 6 items that measure symptom interference with daily life (interference) scored from 0 (did not interfere) to 10 (interfered completely). For symptom burden, total scores range from 0 to 200 and for interference range from 0 to 60, with higher scores indicates high impact on severity of chronic myeloid leukemia-related symptoms and on impact of these symptoms on daily functioning for the patient.
Results for this outcome have not been posted.
Collected over From first dose of study treatment up to the cut-off date for the Week 48 primary analysis (12-Mar-2024), approximately 29 months.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Asciminib 40 mg b.i.d. - Subjects Without MMR at Baseline | 0/85 (0%) | 9/84 (10.7%) | 67/84 (79.8%) |
| Asciminib 80 mg q.d. - Subjects Without MMR at Baseline | 1/84 (1.2%) | 9/84 (10.7%) | 67/84 (79.8%) |
| Asciminib 40 mg b.i.d. - Subjects With MMR at Baseline | 0/14 (0%) | 4/14 (28.6%) | 12/14 (85.7%) |
| Asciminib 80 mg q.d. - Subjects With MMR at Baseline | 0/16 (0%) | 5/16 (31.3%) | 15/16 (93.8%) |
| Event | Asciminib 40 mg b.i.d. - Subjects Without MMR at Baseline | Asciminib 80 mg q.d. - Subjects Without MMR at Baseline | Asciminib 40 mg b.i.d. - Subjects With MMR at Baseline | Asciminib 80 mg q.d. - Subjects With MMR at Baseline |
|---|---|---|---|---|
| Coronary artery diseaseCardiac disorders | 0/84 | 0/84 | 1/14 | 0/16 |
| Blindness unilateralEye disorders | 0/84 | 0/84 | 1/14 | 0/16 |
| Incisional herniaInjury, poisoning and procedural complications | 0/84 | 0/84 | 1/14 | 0/16 |
| Lipase increasedInvestigations | 0/84 | 0/84 | 1/14 | 0/16 |
| Angina pectorisCardiac disorders | 0/84 | 1/84 | 0/14 | 1/16 |
| Pancreatitis acuteGastrointestinal disorders | 0/84 | 0/84 | 0/14 | 1/16 |
| Dengue feverInfections and infestations | 0/84 | 0/84 | 0/14 | 1/16 |
| HyperkalaemiaMetabolism and nutrition disorders | 0/84 | 0/84 | 0/14 | 1/16 |
| Cervicobrachial syndromeNervous system disorders | 0/84 | 0/84 | 0/14 | 1/16 |
| HypertriglyceridaemiaMetabolism and nutrition disorders | 0/84 | 2/84 | 0/14 | 0/16 |
| Event | Asciminib 40 mg b.i.d. - Subjects Without MMR at Baseline | Asciminib 80 mg q.d. - Subjects Without MMR at Baseline | Asciminib 40 mg b.i.d. - Subjects With MMR at Baseline | Asciminib 80 mg q.d. - Subjects With MMR at Baseline |
|---|---|---|---|---|
| PruritusSkin and subcutaneous tissue disorders | 12/84 | 5/84 | 3/14 | 5/16 |
| DiarrhoeaGastrointestinal disorders | 7/84 | 6/84 | 1/14 | 4/16 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 10/84 | 13/84 | 3/14 | 4/16 |
| MyalgiaMusculoskeletal and connective tissue disorders | 5/84 | 4/84 | 2/14 | 4/16 |
| HeadacheNervous system disorders | 8/84 | 8/84 | 2/14 | 4/16 |
| COVID-19Infections and infestations | 11/84 | 9/84 | 3/14 | 3/16 |
| NauseaGastrointestinal disorders | 6/84 | 8/84 | 0/14 | 3/16 |
| BronchitisInfections and infestations | 2/84 | 4/84 | 0/14 | 3/16 |
| Abdominal painGastrointestinal disorders | 5/84 | 5/84 | 2/14 | 2/16 |
| FatigueGeneral disorders | 3/84 | 12/84 | 1/14 | 1/16 |
| Age, Customized(Participants) | Asciminib 40 mg b.i.d. - Subjects Without MMR at Baseline | Asciminib 80 mg q.d. - Subjects Without MMR at Baseline | Asciminib 40 mg b.i.d. - Subjects With MMR at Baseline | Asciminib 80 mg q.d. - Subjects With MMR at Baseline | Total |
|---|---|---|---|---|---|
| 18 - < 65 years | 64 | 59 | 9 | 11 | 143 |
| 65 - < 75 years | 12 | 19 | 4 | 3 | 38 |
| >=75 years | 9 | 6 | 1 | 2 | 18 |
| Sex: Female, Male(Participants) | Asciminib 40 mg b.i.d. - Subjects Without MMR at Baseline | Asciminib 80 mg q.d. - Subjects Without MMR at Baseline | Asciminib 40 mg b.i.d. - Subjects With MMR at Baseline | Asciminib 80 mg q.d. - Subjects With MMR at Baseline | Total |
|---|---|---|---|---|---|
| Female | 37 | 27 | 6 | 6 | 76 |
| Male | 48 | 57 | 8 | 10 | 123 |
| Race (NIH/OMB)(Participants) | Asciminib 40 mg b.i.d. - Subjects Without MMR at Baseline | Asciminib 80 mg q.d. - Subjects Without MMR at Baseline | Asciminib 40 mg b.i.d. - Subjects With MMR at Baseline | Asciminib 80 mg q.d. - Subjects With MMR at Baseline | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 21 | 21 | 2 | 2 | 46 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 4 | 2 | 0 | 0 | 6 |
| White | 58 | 60 | 12 | 14 | 144 |
| More than one race | 1 | 0 | 0 | 0 | 1 |
| Unknown or Not Reported | 1 | 1 | 0 | 0 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Ran from Oct 2021 to primary completion in Mar 2024, 28 months.
Results were first posted in Mar 2025, 1 year after primary completion.
Of 24 phase 3 interventional studies under Leukemia, Myelogenous, Chronic, BCR-ABL Positive, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 79. This study's 28 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Asciminib
Leukemia, Myelogenous, Chronic, BCR-ABL Positive →